Alnylam to share progress across its transthyretin amyloidosis franchise including additional analyses of the HELIOS-B phase III Study Results at Heart Failure 2025 Congress
Alnylam Pharmaceuticals, Inc. announced that the Company will present the latest data from its flagship transthyretin amyloidosis (TTR) franchise at the upcoming Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The latest analyses of the HELIOS-B Phase III study of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), including further outcomes data on cardiovascular hospitalizations and urgent heart failure visits up to 42-months, will be presented as a late-breaking abstract.
Data from the HELIOS-B study supported the recent approvals of Amvuttra (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults in the U.S. and Brazil. These data also supported the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommending approval of vutrisiran for the same indication.
Details are as follows:
Title: Vutrisiran Reduces All-Cause Mortality, Cardiovascular Mortality, and Cardiovascular Events in Patients with Transthyretin Amyloid Cardiomyopathy: Analysis from the HELIOS-B Trial
Session: Hottest Trials and Trial Updates 1
Date: Saturday, May 17,
Presenting Author:: Dr. Marianna Fontana, HELIOS-B investigator, Professor of Cardiology, University College London,
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins